Pharmacokinetics of Different Formulations of Tioctic (Alpha-Lipoic) Acid in Healthy Volunteers

References

• Snell EE, Strong FM, Peterson WH. Growth factors for bacteria. VI: Fractionation and properties of an accessory factor for lactic acid bacteria. Biochem J. 1937; 31: 1789–1799
   PubMedGoogle Scholar
• Reed LJ. Multienzyme complexes. Acc Chem Res 1974; 7: 40–65
   Web of Science ®Google Scholar
• Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med. 1995; 19: 227–250
   PubMed Web of Science ®Google Scholar
• Scholich H, Murphy ME, Sies H. Antioxidant activity of dihydrolipoate against microsomal lipid peroxidation and its dependence on alpha-tocopherol. Biochim Biophys Acta. 1989; 1001: 256–261
   PubMed Web of Science ®Google Scholar
• Busse E, Zimmer G, Schopohl B, Kornhuber B. Influence of alpha-lipoic acid on intracellular glutathione in vitro and in vivo. Arzneimittelforschung. 1992; 42: 829–831
   PubMed Web of Science ®Google Scholar
• Kagan VE, Serbinova EA, Koynova GM, Kitanova SA, Tyurin VA, Stoytchev TS, Quinn PJ, Packer L. Antioxidant action of ubiquinol homologues with different isoprenoid chain length in biomembranes. Free Radic Biol Med. 1990; 9: 117–126
   PubMed Web of Science ®Google Scholar
• Jorg J, Metz F, Scharafinski H. Drug treatment of diabetic polyneuropathy with alpha-lipoic acid or vitamin B preparations. A clinical and neurophysiologic study. Nervenarzt. 1988; 59: 36–44
   PubMed Web of Science ®Google Scholar
• Ziegler D, Mayer P, Muehlen H, Gries FA. Effekte einer Therapie mit alpha-liponsaeure gegenueber Vitamin B1 bei der diabetischen neuropathie. Diabetes Stoffw. 1993; 2: 443–447
   Google Scholar
• Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A three-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995; 38: 1425–1433
   PubMed Web of Science ®Google Scholar
• Nourooz-Zadeh J, Rahimi A, Tajaddini-Sarmadi J, et al. Relationships between plasma measures of oxidative stress and metabolic control in NIDDM. Diabetologia. 1997; 40: 647–653
   PubMed Web of Science ®Google Scholar
• Ziegler D, Schatz H, Conrad F, et al. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients: A four-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care. 1997; 20: 369–373
   PubMed Web of Science ®Google Scholar
• Ziegler D, Gries FA. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes. 1997; 46: S62–S66
   PubMed Web of Science ®Google Scholar
• Borcea V, Nourooz-Zadeh J, Wolff SP, et al. Alpha-lipoic acid decreases oxidative stress even in diabetic patients with poor glycemic control and albuminuria. Free Radic Biol Med. 1999; 26: 1495–1500
   PubMed Web of Science ®Google Scholar
• Haak ES, Usadel KH, Kohleisen M, et al. The effect of alpha-lipoic acid on the neurovascular reflex arc in patients with diabetic neuropathy assessed by capillary microscopy. Microvasc Res. 1999; 58: 28–34
   PubMed Web of Science ®Google Scholar
• Rehmann A, Nourooz-Zadeh J, Moller W, et al. Increased oxidative damage to all DNA bases in patients with type II diabetes. FEBS Lett. 1999; 448: 120–122
   PubMed Web of Science ®Google Scholar
• Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: A seven-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care. 1999; 22: 1296–1301
   PubMed Web of Science ®Google Scholar
• http://www.idi.it/ric/ce/helsinki.pdf, World Medical Association Declaration of Helsinki. 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. Available at
   Google Scholar
• Breithaupt-Grögler K, Niebch G, Schneider E, et al. Dose-proportionality of oral thioctic acid—coincidence of assessments via pooled plasma and individual data. Eur J Clin Pharmacol Sci. 1999; 8: 57–65
   PubMed Web of Science ®Google Scholar
• Mignini F, Streccioni V, Tomassoni D, Traini E, Amenta F. Comparative crossover, randomised, open-label bioequivalence study on the bioequivalence of two formulations of thioctic acid in healthy volunteers. Clin Exp Hypertens 2007; 29: 579–586
   Google Scholar
• European Agency for the Evaluation of Medical Products (EMEA) Committee for Proprietary Medical Products (CPMP). Note for guidance on the investigation of bioavailability and bioequivalence. London 2001, Available at:,
   Google Scholar
• FDA Guidance for Industry. Statistical approaches to establishing bioequivalence. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Washington, DC 2001, Available at:,
   Google Scholar
• Chen J, Jiang W, Cai J, Tao W, Gao X, Jiang X. Quantification of lipoic acid in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2005; 824: 249–257
   PubMed Web of Science ®Google Scholar
• Hodges JR, Lehmann EL. Estimates of location base on rank tests. Annals of Mathematical Statistics 1963; 34: 598–611
   Google Scholar
• Vasdev S, Ford CA, Parai S, Longerich L, Gadag V. Dietary lipoic acid supplementation prevents fructose-induced hypertension in rats. Nutr Metab Cardiovasc Dis. 2000; 10: 339–346
   PubMed Web of Science ®Google Scholar
• Vasdev S, Ford CA, Parai S, Longerich L, Gadag V. Dietary alpha-lipoic acid supplementation lowers blood pressure in spontaneously hypertensive rats. J Hypertens. 2000; 18: 567–573
   PubMed Web of Science ®Google Scholar
• Vasdev S, Gill V, Longerich L, Parai S, Gadag V. Salt-induced hypertension in WKY rats: prevention by alpha-lipoic acid supplementation. Mol Cell Biochem. 2003; 254: 319–326
   PubMed Web of Science ®Google Scholar
• Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest. 1996; 97: 1916–1923
   PubMed Web of Science ®Google Scholar
• Noll G, Tschudi M, Nava E, Luscher TF. Endothelium and high blood pressure. Int J Microcirc Clin Exp. 1997; 17: 273–279
   PubMedGoogle Scholar
• Pechanova O, Kashiba M, Inoue M. Role of glutathione in stabilization of nitric oxide during hypertension developed by inhibition of nitric oxide synthase in the rat. Jpn J Pharmacol. 1999; 81: 223–229
   PubMedGoogle Scholar
• Zicha J, Dobesova Z, Kunes J. Relative deficiency of nitric oxide-dependent vasodilation in salt-hypertensive Dahl rats: The possible role of superoxide anions. J Hypertens. 2001; 19: 247–254
   PubMed Web of Science ®Google Scholar
• Kunes J, Hojna S, Kadlecova M, Dobesova Z, Rauchova H, Vokurkova M, Loukotova J, Pechanova O, Zicha J. Altered balance of vasoactive systems in experimental hypertension: the role of relative NO deficiency. Physiol Res. 2004; 53: S23–S34
   PubMed Web of Science ®Google Scholar
• Pechanova O, Rezzani R, Babal P, Bernatova I, Andriantsitohaina R. Beneficial effects of provinols: Cardiovascular system and kidney. Physiol Res. 2006; 55: S17–S30
   PubMed Web of Science ®Google Scholar
• de Champlain J, Wu R, Girouard H, Karas M, El Midaoui A, Laplante MA, Wu L. Oxidative stress in hypertension. Clin Exp Hypertens. 2004; 26: 593–601
   PubMed Web of Science ®Google Scholar
• Teichert J, Kern J, Tritschler HJ, Ulrich H, Preiss R. Investigations on the pharmacokinetics of alpha-lipoic acid in healthy volunteers. Int J Clin Pharmacol Ther. 1998; 36: 625–628
   PubMed Web of Science ®Google Scholar
• Teichert J, Tuemmers T, Achenbach H, Preiss C, Hermann R, Ruus P, Preiss R. Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease. J Clin Pharmacol. 2005; 45: 313–328
   PubMed Web of Science ®Google Scholar
• Hermann R, Wildgrube HJ, Ruus P, Niebch G, Nowak H, Gleiter CH. Gastric emptying in patients with insulin dependent diabetes mellitus and bioavailability of thioctic acid-enantiomers. Eur J Pharm Sci. 1998; 6: 27–37
   PubMed Web of Science ®Google Scholar
• Teichert J, Tuemmers T, Achenbach H, Preiss C, Hermann R, Ruus P, Preiss R. Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease. J Clin Pharmacol. 2005; 45: 313–328
   PubMed Web of Science ®Google Scholar
• Evans JL, Heymann CJ, Goldfine ID, Gavin LA. Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of alpha-lipoic acid. Endocr Pract. 2002; 8: 29–35
   PubMedGoogle Scholar
• Bernkop-Schnürch A, Reich-Rohrwig E, Marschütz M, Schuhbauer H, Kratzel M. Development of a sustained release dosage form for alpha-lipoic acid. II. Evaluation in human volunteers. Drug Dev Ind Pharm. 2004; 30: 35–42
   PubMed Web of Science ®Google Scholar
• Packer L, Roy S, Sen CK. Alpha-lipoic acid: A metabolic antioxidant and potential redox modulator of trascription. Adv Pharmacol. 1997; 38: 79–101
   PubMedGoogle Scholar
• Packer L, Witt E, Tritschler H. Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med. 1995; 19: 227–250
   PubMed Web of Science ®Google Scholar
• Moini H, Tirosh O, Park YC, Cho K-JC, Packer L. R-alpha-lipoic acid action on cell redox status, the insulin receptor and glucose uptake in 3T3-L1 adipocytes. Arch Biochem Biophys. 2002; 397: 384–391
   PubMed Web of Science ®Google Scholar
• Han D, Handelman G, Marcocci L, Sen CK, Roy S, Kobuchi H, Tritschler HJ, Flohé L, Packer L. Lipoic acid increases de novo synthesis of cellular glutathione by improving cystine utilization. Biofactors. 1997; 6: 321–338
   PubMed Web of Science ®Google Scholar